AmunBio Analysis
What is AmunBio?
AmunBio develops engineered immunotherapeutic oncolytic viruses to treat cancer and hematological malignancies. The platform combines direct cancer cell destruction with immune system activation. The technology targets both solid tumors and blood cancers.
Location
Seattle, United States
Employees
1-10
Founded
2020
Funding Status
Seed
Product Features & Capabilities
- Engineered immunotherapeutic oncolytic viruses for cancer and hematological malignancies
Use Cases
Treat patients with solid tumors; Target hematological malignancies such as leukemia and lymphoma; Activate immune response against cancer cells; Destroy cancer cells directly; Develop therapies for rare cancers
Other Considerations
Early stage biotechnology company; Founded in 2020; HQ in Seattle, WA; Focus on engineered oncolytic virus platform
See something that needs updating? Suggest edits to this profile.